Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$44.63M+4426.33%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Justin Schreiber
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 350
- Beta
- 2.16
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -2.91
Financials
Revenue
$44.63M+4426.3%Net Income
$-4.47MEBITDA
$-2.41MFree Cash Flow
$-2.44MEPS (diluted)
$-0.11Shares Outstanding (diluted)
48.18M+541.0%Operating Expenses
$33.16MCash & Debt
$21.92MReturn of Capital
$776.6KRevenue by Segment (annual)
$12.90MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $194.06M | $-7.11M | $-0.23 |
| 2024 | $212.45M | $-18.88M | $-0.53 |
| 2023 | $152.55M | $-20.60M | $-0.70 |
| 2022 | $119.03M | $-45.54M | $-1.57 |
| 2021 | $92.88M | $-60.90M | $-2.27 |
| 2020 | $37.29M | $-58.65M | $-4.24 |
| 2019 | $12.47M | $-3.14M | $-0.36 |
| 2018 | $8.32M | $-1.24M | $-0.14 |
| 2017 | $5.05M | $-1.21M | $-0.14 |
| 2016 | $5.24M | $-1.11M | $-0.16 |
| 2015 | $1.22M | $-62.0K | $-0.01 |
| 2014 | $714.2K | $-460.5K | $-0.08 |
| 2013 | $808.4K | $-268.3K | $-0.05 |
| 2012 | $673.8K | $-445.6K | $-0.08 |
Valuation
LFMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
45-72.56%Social Signal Score
Mentions (7)
- Newsfool.com·8d ago·Neutral
LifeMD: 3 Key Takeaways for Long-Term Investors LifeMD partnered with Eli Lilly and Novo Nordisk for direct GLP-1 fulfillment. AT&T collaboration grants 100 million customers free LifeMD virtual healthcare access.
View source ↗ - Newsseekingalpha.com·9d ago·Positive
LifeMD, Inc. (LFMD) Q3 2026 Earnings Call Transcript LifeMD, Inc. (LFMD) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
LifeMD Reschedules Third Quarter 2026 Earnings Release and Conference Call to November 12, 2026 NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that the Company has rescheduled its third quarter 2026 earnings release and conference call to Thursday, November 12, 2026.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
LifeMD expands access to Lilly's self-pay GLP-1 medicines, enabling option to dispense and ship directly to patients nationwide Eligible patients prescribed Zepbound® or Foundayo® through LifeMD can now receive authentic Lilly medicines at Lilly's self-pay prices through LifeMD's affiliated pharmacy Eligible patients prescribed Zepbound® or Foundayo® through LifeMD can now receive authentic Lilly medicines at Lilly's self-pay prices through LifeMD's affiliated pharmacy
View source ↗ - Newsglobenewswire.com·61d ago·Negative
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.
View source ↗ - Newszacks.com·67d ago·Positive
AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares? T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
…pite Earnings Miss LifeMD remains a Buy despite disappointing Q2 2026 results, with revenue and EBITDA guidance revised downward and a sequential subscriber decline. LFMD's core business model is profitable at an 88% gross margin, but elevated customer acquisition costs—now 59% of revenue—are pressuring EBITDA. Management is shifting strategy from auction-based marketing to partnerships with manufacturers, employers, and insurers, aiming to reduce CAC and leverage branded GLP-1 therapies.
View source ↗
Earnings
Mon, Mar 8(in 4 months)
Consensus estimate $0.03 per share
Typical surprise -54.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.11 vs $-0.14beat
- Wed, Aug 5$-0.16 vs $-0.15miss
- Wed, May 6$-0.20 vs $-0.14miss
- Mon, Mar 9$-0.04 vs $-0.01miss
- Mon, Nov 17$-0.10 vs $-0.06miss
- Mon, Aug 4$-0.05 vs $0.18miss
Estimates and results for LFMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LFMD officers and directors.
- Bought
- $199k
- Sold
- $5.7m
3 trades
16 trades
- Friedeman Jessicasold
- Alvarez Nicholas Psold
- Schreiber Justinsold
- Schreiber Justinsold
- Benathen Marc Davidsold
- Benathen Marc Davidsold
- Yecies Eric Haroldsold
- Galluppi Stefansold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LFMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
